

USSN: 10/625,204

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph at page 10, line 26 to page 11, line 2 with paragraph set forth below. Applicants note that the paragraph set forth below reflects the text as amended on March 6, 2007.

In a further aspect, the invention provides a cell line such as a hybridoma that produces antibodies, preferably monoclonal antibodies, against the C-type lectins on dendritic cells, more specifically against the peptide with the amino acid sequence shown in/encoded for by SEQ ID NOs: 1 and 2 and Figure 9 or (an antigenic) part thereof. Hybridomas that produce the above mentioned monoclonals AZN-1 and AZN-2 of the invention were deposited on April 8, 1999 with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom, under ~~(provisional)~~ ECACC accession numbers 99040818 and 99040819, respectively.

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph starting at page 1, line 2 with the paragraph set forth below. Applicants note that the paragraph set forth below was introduced by Preliminary Amendment filed concurrently with the instant Application on July 23, 2003.

This application is a divisional of U.S. Application No. 09/719,961 filed 24 September 2001, now U.S. Patent No. 7,148,329, which is a U.S. National Stage filing of International Application No. PCT/NL00/00253 filed 19 April 2000, which claims priority to EP Application No. 99201204.7 filed 19 April 1999. International Application No. PCT/NL00/00253 additionally claims ~~priority to the benefit of~~ U.S. Application No. 60/176,924, filed 20 January 2000. All of the foregoing applications are hereby incorporated herein by reference in their entirety.

Please replace the paragraph at page 3, lines 1-9, with the following marked up paragraph:

Curtis et al., in *Proc. Natl. Acad. Sci. USA*, 89 (1992), p. 8356-8360, as well as in WO 93/01820, describe a non-CD4 gp120 receptor isolated and cloned from human placenta tissue. This gp120 receptor is expressed on mammalian cells which do not exhibit high levels of CD4, such as placenta, skeleton muscle, brain, neural and mucosal cells, as well as other tissues and cells including colon, thymus, heart, T cells, B cells and macrophages (but not in the liver or the kidney). The amino acid sequence of the C-type lectin gp120 receptor disclosed in SEQ ~~ID's no.~~ ID NOs: 1 and 2 of WO 93/01820 ~~has a high degree of sequence homology (>98%) with is~~ is identical to the C-type lectins that are now found to be present on dendritic cells.

Please replace the paragraph at page 6, lines 13-24, with the marked up paragraph set forth below. Applicants note that paragraph set forth below represents the text of the paragraph as amended by the preliminary amendment filed concurrently with the instant Application on July 23, 2003.

The amino acid sequence of one C-type lectin that was found to be involved in the binding of the dendritic cells to the T-cells is shown in SEQ ID NO: 1 and Figure 9. This C-type lectin receptor is ~~essentially similar to~~ identical to the C-type lectin gp120 receptor described by Curtis et al. in *Proc. Natl. Acad. Sci. USA*, 89 (1992), p. 8356-8360 and ~~in the amino acid sequence given in SEQ ID NO: 1 of WO 93/01820. In particular, it has a high degree of homology (>98%) to the amino acid sequence given in SEQ ID NO: 1 of WO 93/01820.~~ It is a group II C-type lectin of 404 amino acids; with an apparent Mr of about 44 kDa; and with a first domain (Met 1 to Ala 76) comprising a cytoplasmic amino terminus, a second domain (Ile 77 to Val 249) comprising tandem repeats, and a third domain (Cys 253 to Ala 404) with a high degree of homology to other known C-type lectins which are type II membrane proteins. Further characterization is given below.

Please replace the paragraph at page 10, line 26 to page 11, line 2 with the following marked up paragraph:

In a further aspect, the invention provides a cell line such as a hybridoma that produces antibodies, preferably monoclonal antibodies, against the C-type lectins on dendritic cells, more specifically against the peptide with the amino acid sequence shown in/encoded for by SEQ ID ~~no's~~ NOs: 1 and 2 and Figure 9 or (an antigenic) part thereof. Hybridomas that produce the above mentioned monoclonals AZN-1 and AZN-2 of the invention were deposited on April 8, 1999 with the European Collection of Cell Cultures under (provisional) ECACC accession numbers 990400818-99040818 and 99040819, respectively.